These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

710 related items for PubMed ID: 12522323

  • 1. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ, Ernest P.
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacological therapy of obesity].
    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Orlistat and sibutramine beyond weight loss.
    Mannucci E, Dicembrini I, Rotella F, Rotella CM.
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 8. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N, Ryan DH, Renz CL, Hewkin AC.
    Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K, Sundström J, Neovius K, Rössner S, Neovius M.
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Wang TF, Pei D, Li JC, Tsai WC, Tsai CC, Yao CY, Chang ET, Hsieh MC, Su KY, Kuo SW.
    Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Weight reduction. Antiobesity drug treatment in type-2 diabetics].
    Verspohl EJ.
    Pharm Unserer Zeit; 2002 Jul; 31(3):300-7. PubMed ID: 12071127
    [No Abstract] [Full Text] [Related]

  • 16. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM.
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [Abstract] [Full Text] [Related]

  • 17. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
    Lee M, Aronne LJ.
    Am J Cardiol; 2007 Feb 19; 99(4A):68B-79B. PubMed ID: 17307059
    [Abstract] [Full Text] [Related]

  • 18. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K, Finer N, Rössner S.
    Diabetes Obes Metab; 2008 Jun 19; 10(6):498-505. PubMed ID: 17593239
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.
    Int J Obes (Lond); 2008 Apr 19; 32(4):692-9. PubMed ID: 18071341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.